Table 5.
PathwayID | PathwayName | p-value | AE | RE | MJI | C |
---|---|---|---|---|---|---|
1430728 | Metabolism | 4.32E-35 | 525 | 2.19 | 0.34 | 93 |
556833 | Metabolism of lipids and lipoproteins | 1.00E-13 | 175 | 2.25 | 0.27 | 91 |
453279 | Mitotic G1-G1/S phases | 2.41E-42 | 47 | 27.44 | 0.33 | 87 |
200137 | AP-1 transcription factor network | 2.36E-06 | 44 | 2.97 | 0.32 | 87 |
453279 | Mitotic G1-G1/S phases | 2.77E-09 | 78 | 2.73 | 0.30 | 87 |
200120 | Direct p53 effectors | 6.09E-07 | 70 | 2.4 | 0.27 | 85 |
69278 | Cell Cycle, Mitotic | 1.81E-14 | 166 | 2.37 | 0.28 | 82 |
1640170 | Cell Cycle | 1.51E-12 | 183 | 2.11 | 0.26 | 80 |
535734 | Fatty acid, triacylglycerol, and ketone body metabolism | 1.38E-07 | 81 | 2.35 | 0.26 | 79 |
71291 | Metabolism of amino acids and derivatives | 7.54E-15 | 120 | 2.9 | 0.33 | 76 |
DiseaseID | DiseaseName | p-value | AE | RE | MJI | C |
MESH:D015228 | Hypertriglyceridemia | 1.60E-192 | 4573 | 2.09 | 0.77 | 79 |
MESH:D009468 | Neuromuscular Diseases | 4.34E-07 | 117 | 2.04 | 0.41 | 74 |
MESH:D009468 | Neuromuscular Diseases | 2.16E-293 | 4573 | 2.52 | 0.82 | 74 |
MESH:D052016 | Mucositis | 4.99E-199 | 4572 | 2.11 | 0.77 | 72 |
MESH:D002543 | Cerebral Hemorrhage | 7.21E-128 | 4572 | 1.8 | 0.73 | 72 |
MESH:D006463 | Hemolytic-Uremic Syndrome | 3.65E-215 | 4570 | 2.18 | 0.78 | 72 |
MESH:D020246 | Venous Thrombosis | 6.59E-106 | 4573 | 1.71 | 0.72 | 70 |
MESH:D013923 | Thromboembolism | 1.78E-123 | 4573 | 1.79 | 0.73 | 70 |
DrugID | DrugName | p-value | AE | RE | MJI | C |
PA449383 | Docetaxel | 3.08E-02 | 52 | 1.89 | 0.36 | 24 |
PA449780 | Glutathione | 1.74E-10 | 20 | 10.48 | 0.24 | 13 |
PA131301952 | Gefitinib | 8.52E-17 | 29.88 | 10.84 | 0.395 | 8 |
PA451283 | Rosiglitazone | 7.73E-22 | 41.4 | 10.58 | 0.386 | 5 |
PA448803 | Carboplatin | 2.57E-15 | 27 | 11.36 | 0.397 | 5 |
OrganID | OrganName | p-value | AE | RE | MJI | C |
liver | Liver | 1.82E-17 | 179 | 2.72 | 0.40 | 84 |